BridgeMD
Prevention study for Delirium
Official title Effect of Nasal Spray Dexmedetomidine on Emergence Delirium Prevention in Total Hip Replacement
ClinicalTrials.gov ID: NCT06579001
What this study is testing
What is Nasal spray dexmedetomidine?
Nasal spray dexmedetomidine is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for delirium.
Also referred to as saline.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Emergence Delirium (ED) is a common postoperative complication refers to an acute brain dysfunction that occurs during the recovery from general anesthesia, which is mainly characterized by sudden attention and consciousness disorders. The occurrence of ED increases the risk of self-injury, wound dehiscence, accidental catheter dislocation, and postoperative delirium, and is also associated with postoperative cognitive deterioration and increased utilization of medical resources after discharge.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 60 and older
You may be able to join if
- Age ≥60 years old
- Total hip arthroplasty under general anesthesia
- ASA II-III
- Informed consent was obtained from patients or their guardians
You likely can't join if
- Allergy or contraindication to dexmedetomidine
- Severe rhinitis and nasal deformity
- Severe bradycardia (heart rate \<50 beats/minute) or atrioventricular block of grade 2 or higher, permanent pacemaker implantation, severe heart...
- Patients with previous myocardial infarction, unstable angina pectoris, severe arrhythmia, and cardiac insufficiency
- Emergency surgery
- Severe hepatic and renal dysfunction (Child-Pugh class B and C, CKD3-5)
See the full eligibility criteria
- Age ≥60 years old
- Total hip arthroplasty under general anesthesia
- ASA II-III
- Informed consent was obtained from patients or their guardians
- Allergy or contraindication to dexmedetomidine
- Severe rhinitis and nasal deformity
- Severe bradycardia (heart rate \<50 beats/minute) or atrioventricular block of grade 2 or higher, permanent pacemaker implantation, severe heart failure or ejection fraction \<30%
- Patients with previous myocardial infarction, unstable angina pectoris, severe arrhythmia, and cardiac insufficiency
- Emergency surgery
- Severe hepatic and renal dysfunction (Child-Pugh class B and C, CKD3-5)
- Preoperative mental illness, cognitive impairment, and communication difficulties could not be evaluated in the study
- Preoperative delirium was present
The study team makes the final eligibility decision.
Where it's taking place
- Hangzhou, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 60 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hangzhou, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.